Drug Trial Radar · NCT04641338
Fixed Combination of Dipyrone and Codeine for Controlling Pain After Pelvic-abdominal Surgery
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
491
Actual
Start
Mar 16, 2023
Primary completion
Mar 15, 2024
Study completion May 17, 2024
Sponsor
- Lead sponsor
- Brazilian Clinical Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Brainfarma Industria Química e Farmacêutica S/A
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III clinical trial, multicentre, superiority, randomized, open, parallel groups, with active control and use of postoperative oral medication (multiple doses of medication).
Conditions
- Pain, Postoperative
Interventions
Fixed dose combination Dipyrone and CodeineDrug
Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours
DipyroneDrug
use of 1000 mg dipyrone every 6 hours
CodeineDrug
30 mg codeine every 6 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving at least 50% of maximum pain relief within 6 hoursTime frame: 6 hours
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Associação Hospital de Caridade Ijuí - Núcleo de Ensino e Pesquisa
Ijuí, Rio Grande do Sul, Brazil
Hospital Universitário São Francisco na Providência de Deus
Bragança Paulista, São Paulo, Brazil
Santa Casa de Misericórdia de Votuporanga
Votuporanga, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.